Paroxetine Mesylate

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598523

CAS#: 217797-14-3

Description: Paroxetine Mesylate is a serotonin uptake inhibitor that is effective in the treatment of depression.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-07-11. Prices are subject to change without notice.

Paroxetine Mesylate is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 598523
Name: Paroxetine Mesylate
CAS#: 217797-14-3
Chemical Formula: C20H24FNO6S
Exact Mass: 425.1308
Molecular Weight: 425.47
Elemental Analysis: C, 56.46; H, 5.69; F, 4.47; N, 3.29; O, 22.56; S, 7.54

Synonym: Paroxetine Mesylate; Pexeva; POT.mes; Paroxetine Mesilate; LDMP; Brisdelle;

IUPAC/Chemical Name: (3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine methanesulfonate


InChi Code: InChI=1S/C19H20FNO3.CH4O3S/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;1-5(2,3)4/h1-6,9,14,17,21H,7-8,10-12H2;1H3,(H,2,3,4)/t14-,17-;/m0./s1

SMILES Code: FC1=CC=C([C@H]2[C@H](COC3=CC=C(OCO4)C4=C3)CNCC2)C=C1.CS(=O)(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Carris N, Kutner S, Reilly-Rogers S. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate. Ann Pharmacother. 2014 Oct;48(10):1343-9. doi: 10.1177/1060028014543099. Epub 2014 Jul 15. Review. PubMed PMID: 25028744.

2: Cristina Castelli M, Bhaskar S, Lippman J. Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. Clin Ther. 2013 Jun;35(6):862-9. doi: 10.1016/j.clinthera.2013.05.001. PubMed PMID: 23795577.

3: Slaton RM, Champion MN, Palmore KB. A review of paroxetine for the treatment of vasomotor symptoms. J Pharm Pract. 2015 Jun;28(3):266-74. doi: 10.1177/0897190014544785. Epub 2014 Aug 8. Review. PubMed PMID: 25107421.

4: Weber L, Thacker HL. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women. Womens Health (Lond). 2014 Mar;10(2):147-54. doi: 10.2217/whe.14.3. Review. PubMed PMID: 24601805.

5: Pae CU, Misra A, Ham BJ, Han C, Patkar AA, Masand PS. Paroxetine mesylate: comparable to paroxetine hydrochloride? Expert Opin Pharmacother. 2010 Feb;11(2):185-93. doi: 10.1517/14656560903451708. Review. PubMed PMID: 20088740.

6: Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health. 2015 Jun 18;7:615-24. doi: 10.2147/IJWH.S50804. eCollection 2015. Review. PubMed PMID: 26124682; PubMed Central PMCID: PMC4476484.

7: van den Tweel ER, Relleke M, Muniz Piniella P. Paroxetine oral solution is bioequivalent to paroxetine tablets--advantages of the solution. Int J Clin Pharmacol Ther. 2007 Nov;45(11):611-6. PubMed PMID: 18077927.

8: Vergouwen AC, Bakker A. [Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCl hemihydrate]. Ned Tijdschr Geneeskd. 2002 Apr 27;146(17):811-2. Dutch. PubMed PMID: 12014241.

9: Kaunitz AM, Manson JE. Management of Menopausal Symptoms. Obstet Gynecol. 2015 Oct;126(4):859-76. doi: 10.1097/AOG.0000000000001058. Review. PubMed PMID: 26348174; PubMed Central PMCID: PMC4594172.

10: Goldenberg MM. Pharmaceutical approval update. P T. 2013 Aug;38(8):443-5. PubMed PMID: 24222975; PubMed Central PMCID: PMC3814443.

11: Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003 Jun;25(6):1578-92. Review. PubMed PMID: 12860486.

12: Cada DJ, Levien TL, Baker DE. Dimethyl fumarate. Hosp Pharm. 2013 Sep;48(8):668-79. doi: 10.1310/hpj4808-668. PubMed PMID: 24421538; PubMed Central PMCID: PMC3847980.

13: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Dec;32(10):749-73. doi: 10.1358/mf.2010.32.10.1573763. PubMed PMID: 21225012.

14: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Nov;32(9):675-703. doi: 10.1358/mf.2010.32.9.1563109. PubMed PMID: 21225019.

15: Cutaneous drug reaction case reports: from the world literature. Am J Clin Dermatol. 2003;4(5):365-70. PubMed PMID: 12688840.

16: Bayés M, Rabasseda X, Prous JR. Gateways to Clinical Trials. Methods Find Exp Clin Pharmacol. 2002 Sep;24(7):431-55. Review. PubMed PMID: 12428432.

17: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PubMed PMID: 16082422.